statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

EXCLUSIVE: Femasys At Inflection Point And Undervalued, Expects Growth Potential Following Roe v. Wade Overturn, CEO Says

Femasys focuses on innovative women's healthcare solutions. Their FemBloc product, a non-surgical permanent birth control, is in late-stage development, aiming for a $20 billion market.
read more...

Femasys: A Buy Rating on Innovative Reproductive Solutions and Market Expansion Potential

Jason McCarthy, an analyst from Maxim Group, maintained the Buy rating on Femasys (FEMY Research Report). The associated price target remains the...

Femasys price target raised by $2 at H.C. Wainwright, here's why

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Femasys (NASDAQ:FEMY) Posts Quarterly  Earnings Results, Hits Expectations

Femasys (NASDAQ:FEMY - Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.19) earnings per share for the quarter, meeting the consensus estimate of...

FEMY Stock Earnings: Femasys Beats EPS, Misses Revenue for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips
FEMY stock results show that Femasys beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of...

Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update

Following FDA Clearance of FemaSeed , Company Secures Capital to Support Commercial Initiatives; Cash Expected to Fund Operations Into 2H 2025ATLANTA, March 28, 2024 (GLOBE NEWSWIRE) -- Femasys...

Femasys (NASDAQ:FEMY) Price Target Raised to $10.00

Femasys (NASDAQ:FEMY  Free Report) had its price objective hoisted by Jonestrading from $7.00 to $10.00 in a research note published on Wednesday morning, Benzinga reports. The brokerage...

Chardan Capital Reaffirms "Buy" Rating for Femasys (NASDAQ:FEMY)

Chardan Capital reissued their buy rating on shares of Femasys (NASDAQ:FEMY  Free Report) in a research note released on Thursday, Benzinga reports. The firm currently has a $12.00 price...

Femasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment Landscape

-- CEO Kathy Lee-Sepsick and Chief Medical Officer James Liu to Join Jones Trading Analyst Catherine Novack in a Conversation on Current Treatment Options in Infertility Including FemaSeed at 1PM ET...

Femasys announces topline data from trial of FemaSeed for infertility

Femasys, Inc. is a biomedical company, which engages in the development of novel solutions for reproductive healthcare. The company was founded by Kathy Lee-Sepsick in 2004 and is headquartered in Suwanee, GA.

Volume	681,364.00
52-Wk High	$4.75
52-Wk Low	$0.2479

FEMY Femasys Inc

About

Feed

News

Fundamentals